[doptab title=”Overview”]

Wisconsin Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Wisconsin

Wisconsin Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Wisconsin Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Wisconsin Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.


[doptab title=”Treatment and Research”]


[dopaccordions] [dopaccordion title=”Raines, Ronald T. Ribonucleases In Cancer Chemotherapy Grant: 2R01CA073808-04″ icon=27 activeicon=28]

Abstract: DESCRIPTION (from applicant’s abstract): The overall goal of the proposed research is to reveal how homologs and variants of ribonuclease A (RNase A) promote tumor cell death. Onconase, which is an amphibian homolog of RNase A, is now undergoing Phase III human clinical trials for the treatment of malignant mesothelioma and Phase I/II trials for the treatment of metastatic renal carcinoma. In contrast to onconase, RNase A is not cytotoxic. In the initial funding period, variants of RNase A were created that, like onconase, were able to evade the endogenous ribonuclease inhibitor protein (RI) that resides in the cytosol of mammalian cells. These variants were toxic to tumor cells. This finding portends the development of a new class of cancer chemotherapeutics based on homologs and variants of RNase A. The specific aims of the proposed research are: (1) to determine how RNase A homologs bind to the cell surface, (2) to discover the route taken by RNase A homologs to cytosolic RNA, (3) to reveal fundamental information about the subcellular localization and intracellular function of RI, and (4) to create a human homolog of RNase A that is more toxic to tumor cells than onconase. Relevant properties of RNase A homologs and variants will be assessed in comparison to onconase (positive control) and wild-type RNase A (negative control). These properties include cytotoxicity, RI evasion, ribonucleolytic activity, and conformational stability. Finally, the three-dimensional structures of RNase A homologs and variants with notable cytotoxicity will be determined by X-ray diffraction analysis. The proposed research is designed to reveal new insights into the basis of ribonuclease cytotoxicity, and could lead to new cancer chemotherapeutics. 

Tags: Antineoplastic, Cytotoxicity, Enzyme Activity, Enzyme Inhibitor, Pancreatic Ribonuclease Rna, Conformation, Drug Design /synthesis /production, Intracellular Transport X Ray Crystallography, Protein Engineering 

  • Followup Grant: 5R01CA073808-05
  • Followup Grant: 5R01CA073808-06
  • Followup Grant: 5R01CA073808-07
  • Followup Grant: 2R01CA073808-08
  • Followup Grant: 5R01CA073808-09
  • Followup Grant: 5R01CA073808-10
  • Followup Grant: 5R01CA073808-11

[/dopaccordion] [dopaccordion title=”Schiller, Joan H. Mid Career Investigator Award Grant: 1K24CA084172-01″ icon=27 activeicon=28]

Abstract: DESCRIPTION: (Applicant’s Description) This application proposes Joan H. Schiller, M.D., for a K24 Mid-Career Investigator Award in Patient Oriented Research. Dr. Schiller is currently one of only two tenured women physicians in the University of Wisconsin Department of Medicine, and an accomplished medical oncologist with an active clinical and translational research program in lung cancer. Dr. Schiller is active in drug development in lung cancer, participating at all levels of clinical research, including Phase I, II, and III trials. In addition to running an active Phase II program at the UW and participating in the UWCCC Phase I program, she is co-chair of the Eastern Co- Operative Group (ECOG) Thoracic Committee, and chair of two ECOG multi- institutional Phase III studies. Dr. Schiller intends to use the release time from her heavy clinical and administrative responsibilities to expand her scope of clinical research in lung cancer, develop a mentoring program for young investigators, and to further develop her own mentoring and leadership skills. Her specific aims within this award are (1) to draw upon the considerable campus-wide resources in basic and translational research at the UW, so as to facilitate interdisciplinary collaborations and development of a UW clinical lung cancer research program that engages the participation of researchers from multiple disciplines; (2) to develop a mentoring program for residents and fellows for tobacco-related neoplasms and associated clinical research, (3) to support her activities in clinical research in lung cancer, and enhance her own development as an academic leader in the field of lung cancer, and (4) to foster the career development of women clinical scientists and leaders in academic medicine. In this application, Dr. Schiller demonstrates (a) her strong clinical research interest in lung cancer, and accomplishments in the field; (b) an outstanding basic science and clinical environment within the UW in which to conduct patient-oriented, translational research; (c) her unique position within the institution to nurture the careers of women junior investigators, and (d) the need for protected research time to continue these efforts. 

Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Mesothelioma, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Radiation Therapy, Nonsmall Cell Lung Cancer, Small Cell Lung Cancer Angiogenesis Inhibitor, Carboplatin, Cis Platinum Compound, Clinical Trial Phase I, Clinical Trial Phase Ii /iii /iv, Cyclophosphamide, Doxorubicin, Etoposide, Gemcitabine, Guanine Nucleotide Binding Protein, P53 Gene /protein, Paclitaxel, Role Model, Topotecan, Vinblastine, Vincristine Clinical Research, Human Subject 

  • Followup Grant: 5K24CA084172-02
  • Followup Grant: 5K24CA084172-03
  • Followup Grant: 5K24CA084172-04
  • Followup Grant: 5K24CA084172-05

[/dopaccordion] [/dopaccordions]

Clinical Trials

[dopaccordions] [dopaccordion title=”Recruiting AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate;   Other: laboratory biomarker analysis
More Information

[/dopaccordion] [dopaccordion title=”Active, not recruiting Pazopanib in Treating Patients With Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
More Information

[/dopaccordion] [dopaccordion title=”Active, not recruiting Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion] [dopaccordion title=”Active, not recruiting Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
More Information

[/dopaccordion] [dopaccordion title=”Completed Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma” icon=27 activeicon=28]

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

[/dopaccordion] [dopaccordion title=”Recruiting Collecting Tumor Samples From Patients With Gynecological Tumors” icon=27 activeicon=28]

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

[/dopaccordion] [/dopaccordions]
[doptab title=”Doctors and Hospitals”]


Joan H. Schiller, M.D. 
H. Ian Robins, M.D. 
University of Wisconsin 
Madison, WI

[doptab title=”Cases”]

State v. Harenda Enters.
No. 2005AP1829, SUPREME COURT OF WISCONSIN, March 13, 2008, Filed

Sopha v. Owens-Corning Fiberglas Corp.
No. 98-1343, SUPREME COURT OF WISCONSIN, September 10, 1999 , October 27, 1999, Opinion Filed

Tatera v. FMC Corp.
Appeal No. 2008AP170, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, May 12, 2009, Decided, May 12, 2009, Filed

Zielinski v. A.P. Green Indus.
Appeal No. 02-1888 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, February 4, 2003, Submitted On Briefs , March 18, 2003, Decided , March 18, 2003, Filed

Anderson v. Combustion Eng’g, Inc.
Appeal No. 01-1518, COURT OF APPEALS OF WISCONSIN, DISTRICT I, May 7, 2002, Oral Argument , May 21, 2002, Decided , May 21, 2002, Filed

Int’l Paper Co. v. Labor & Indus. Review Comm’n
No. 01-0126, COURT OF APPEALS OF WISCONSIN, DISTRICT THREE, July 23, 2001, Submitted On Briefs , September 25, 2001, Decided , September 25, 2001, Filed

Kasun v. Owens-Illinois, Inc.
No. 00-2550, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, August 14, 2001, Decided , August 14, 2001, Filed

Sybron Int’l Corp. v. Sec. Ins. Co.
No. 99-3050 , COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, March 6, 2001, Decided , March 6, 2001, Filed

Stendahl v. A & M Insulation Co.
No. 99-0212, COURT OF APPEALS OF WISCONSIN, DISTRICT ONE, October 10, 2000, Decided , October 10, 2000, Filed

[doptab title=”Lawyers”]

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

  • This field is for validation purposes and should be left unchanged.